Le Lézard
Classified in: Health
Subjects: PDT, FDA

Aerin Medical Achieves Significant Milestone with over 1,000 Patients Treated with VIVAER


AUSTIN, Texas, July 31, 2018 /PRNewswire/ -- Aerin Medical, Inc. ("Aerin") announced that over 1,000 patients suffering from nasal obstruction have successfully received the VIVAER® Nasal Airway Remodeling treatment ("VIVAER") which uses patented non-invasive low temperature radio frequency technology to reshape nasal tissues.

Aerin Medical, Inc.

The company received FDA clearance for VIVAER last December following a highly successful clinical study which produced best-in-class outcomes, including a 94% responder rate with an average improvement in breathing ability of 69% as measured by NOSE (Nasal Obstruction Symptom Evaluation) scores. In January of this year, Aerin initiated a limited commercial rollout of VIVAER in the United States and is currently expanding its distribution and support network with a dedicated team of sales professionals within the US.

"ENT physicians are quickly discovering how VIVAER enhances their abilities to comprehensively treat patients suffering from nasal breathing problems.  VIVAER is being used as both a standalone treatment and an adjunct procedure to surgery," stated Fred Dinger, CEO & President of Aerin Medical.  "As a standalone treatment, VIVAER can be a non-invasive option to open nasal passages for those patients who suffer from nasal obstruction or congestion.  VIVAER is also helpful to those patients who have undergone surgical procedures such as septoplasty, turbinate reduction and sinus surgery/dilation but still have trouble breathing," Dinger continued.

Michael Sillers, MD, a world-renowned rhinologist and past president of the American Rhinologic Society stated: "As otolaryngologists, we were trained that the nasal valve is often the primary site of nasal obstruction; however, we have had few effective solutions to treat this area, so it has become largely overlooked. VIVAER is a simple and elegant solution that can be easily performed in the physician's office within minutes and it enables a comprehensive approach to treating patients suffering from nasal obstruction beyond traditional septum and turbinate surgeries."

"We have integrated VIVAER into our 17-physician practice and we routinely treat patients who complain of nasal obstruction, found to be at the nasal valve, especially during sleep and physical activity.  I have treated over twenty patients so far and I am very impressed with the clinical outcomes and convenience experienced by my patients," said Vasu Kakarlapudi, M.D. one of the first otolaryngologists to treat patients using VIVAER in the US.

Aerin continues to follow treated patients and they are reporting improved nasal breathing as well as other benefits such as better-quality sleep and an increased ability to breathe comfortably during physical activity. Aerin also continues to develop its pipeline of non-invasive products/treatments to address other areas of nasal breathing disorders.

Aerin Medical is an early commercialization stage medical device company with offices in Austin, TX, Sunnyvale, CA and Singapore. Aerin is a patient-centric company focused on the development and commercialization of products to improve the breathing and quality of life for millions of people. Aerin Medical and VIVAER are registered trademarks of Aerin Medical, Inc.

 

SOURCE Aerin Medical, Inc.


These press releases may also interest you

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....

at 16:05
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December...

at 16:05
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial...

at 16:05
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023...



News published on and distributed by: